A long-acting erythropoietin fused with noncytolytic human Fc for the treatment of anemia

Archives of Pharmacal Research

Volumn 35, Issue 5, 2012, Pages 757-759

  Yang, Se Hwan ^a   Yang, Sang In ^a   Chung, Yo Kyung ^b  

^a POSTECH Biotech Center   (South Korea)

^b Green Cross Company   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C1Q; ERYTHROPOIETIN; FC RECEPTOR; GLUCAGON LIKE PEPTIDE 1; GX E2; HEMOGLOBIN; HYBRID PROTEIN; IMMUNOGLOBULIN G1; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ANEMIA; ANIMAL EXPERIMENT; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BINDING AFFINITY; COMPLEMENT DEPENDENT CYTOTOXICITY; CRYSTAL STRUCTURE; DISEASE SEVERITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG HALF LIFE; ERYTHROPOIESIS; HEMOGLOBIN BLOOD LEVEL; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; RAT;

ANEMIA; ANIMALS; DELAYED-ACTION PREPARATIONS; ERYTHROPOIETIN; HUMANS; PROTEIN BINDING; RECEPTORS, FC; RECOMBINANT FUSION PROTEINS; TIME FACTORS; TREATMENT OUTCOME; X-RAY DIFFRACTION;

EID: 84862834279     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-012-0500-5     Document Type: Article

References (7)

1. Chamow, S. M. and Ashkenazi, A., Immunoadhesins: principles and applications. Trends Biotechnol., 14, 52-60 (1996).
2. Elliott, S., Lorenzini, T., Asher, S., Aoki, K., Brankow, D., Buck, L., Busse, L., Chang, D., Fuller, J., Grant, J., Hernday, N., Hokum, M., Hu, S., Knudten, A., Levin, N., Komorowski, R., Martin, F., Navarro, R., Osslund, T., Rogers, G., Rogers, N., Trail, G., and Egrie, J., Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat. Biotechnol., 21, 414-421 (2003).
3. Huang, C., Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology. Curr. Opin. Biotechnol., 20, 692-699 (2009).
4. Idusogie, E. E., Wong, P. Y., Presta, L. G., Gazzano-Santoro, H., Totpal, K., Ultsch, M., and Mulkerrin, M. G., Engineered antibodies with increased activity to recruit complement. J. Immunol., 166, 2571-2575 (2001).
5. Im, S. J., Yang, S. I., Yang, S. H., Choi, D. H., Choi, S. Y., Kim, H. S., Jang, do. S., Jin, K. S., Chung, Y. K., Kim, S. H., Paik, S. H., Park, Y. C., Chung, M. K., Kim, Y. B., Han, K. H., Choi, K. Y., and Sung, Y. C., Natural form of noncytolytic flexible human Fc as a long-acting carrier of agonistic ligand, erythropoietin. PLoS ONE, 6, e24574 (2011).
6. Lai, P. H., Everett, R., Wang, F. F., Arakawa, T., and Goldwasser, E., Structural characterization of human erythropoietin. J. Biol. Chem., 261, 3116-3121 (1986).
7. Macdougall, I. C., Optimizing the use of erythropoietic agents- pharmacokinetic and pharmacodynamic considerations. Nephrol. Dial. Transplant., 17 Suppl 5, 66-70 (2002).